Achieved $20.0 million in Revuforj net revenue in the first quarter of 2025, the first full quarter of the U.S. launch. Revuforj was launched in the U.S. in late November 2024 for the treatment of ...

DelveInsight's " Aplastic Anemia Market Insights, Epidemiology, and Market Forecast- 2034" report delivers an in-depth ...

Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.

Incyte today reports 2025 first quarter financial results, and provides a status update on the Company's clinical development portfolio. "The double-digit revenue growth in the first quarter driven by ...

A panelist discusses how the treatment landscape for chronic graft-vs-host disease (cGVHD) has evolved significantly in ...

Approximately two-thirds of patients responded to teduglutide, which is sold under the brand name Gattex as a treatment for ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment reduced daily dosages over 12 months. Patients with myelofibrosis who were ...

Graft-versus-host disease (GVHD) symptoms can range from mild to severe, and all of them can have an impact on your quality of life in different ways. The symptoms of acute GVHD, which often ...

Now, let’s shift our focus to AD. and the emerging role of immune modulators in the treatment of AD. Please discuss the findings presented at AAD 2025 regarding the association of ruxolitinib ...

However, graft-versus-host disease (GvHD) is often observed, which can make data interpretation challenging. To this end, the NCG-MHC-dKO mouse model was developed by knocking out both murine MHC ...